BRIDGEBIO PHARMA INC (BBIO)

US10806X1028 - Common Stock

30.59  -0.27 (-0.87%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BBIO. BBIO was compared to 592 industry peers in the Biotechnology industry. BBIO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BBIO is valued expensive at the moment.



0

1. Profitability

1.1 Basic Checks

In the past year BBIO has reported negative net income.
In the past year BBIO has reported a negative cash flow from operations.
BBIO had negative earnings in each of the past 5 years.
BBIO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -117.72%, BBIO is doing worse than 84.01% of the companies in the same industry.
Industry RankSector Rank
ROA -117.72%
ROE N/A
ROIC N/A
ROA(3y)-83.5%
ROA(5y)-71.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BBIO has been increased compared to 1 year ago.
BBIO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BBIO has a worse debt to assets ratio.

2.2 Solvency

Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.72%

2.3 Liquidity

A Current Ratio of 3.00 indicates that BBIO has no problem at all paying its short term obligations.
BBIO has a worse Current ratio (3.00) than 67.86% of its industry peers.
A Quick Ratio of 3.00 indicates that BBIO has no problem at all paying its short term obligations.
BBIO has a worse Quick ratio (3.00) than 65.99% of its industry peers.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 3

5

3. Growth

3.1 Past

The earnings per share for BBIO have decreased strongly by -26.69% in the last year.
The Revenue for BBIO has decreased by -88.02% in the past year. This is quite bad
Measured over the past years, BBIO shows a small growth in Revenue. The Revenue has been growing by 4.09% on average per year.
EPS 1Y (TTM)-26.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-4.35%
Revenue 1Y (TTM)-88.02%
Revenue growth 3Y4.09%
Revenue growth 5YN/A
Revenue growth Q2Q-6.68%

3.2 Future

Based on estimates for the next years, BBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 25.98% on average per year.
Based on estimates for the next years, BBIO will show a very strong growth in Revenue. The Revenue will grow by 178.61% on average per year.
EPS Next Y6.45%
EPS Next 2Y9.43%
EPS Next 3Y13.83%
EPS Next 5Y25.98%
Revenue Next Year699.82%
Revenue Next 2Y289.62%
Revenue Next 3Y263.15%
Revenue Next 5Y178.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BBIO. In the last year negative earnings were reported.
Also next year BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BBIO's earnings are expected to grow with 13.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.43%
EPS Next 3Y13.83%

0

5. Dividend

5.1 Amount

No dividends for BBIO!.
Industry RankSector Rank
Dividend Yield N/A

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (3/28/2024, 1:09:01 PM)

30.59

-0.27 (-0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.62B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.72%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3
Quick Ratio 3
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-26.69%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y6.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-88.02%
Revenue growth 3Y4.09%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y